« Back
Home /
Menin-MLL inhibitor-22

Menin-MLL inhibitor-22

Item no.	HY-151595-50mg
Manufacturer	MedChem Express
CASRN	2851841-61-5
Amount	50 mg
Quantity options	100 mg 10 mg 1 ea 25 mg 50 mg 5 mg
Specific against	other
Purity	99.85
Citations	[1]Lei H, et al. Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups. J Med Chem. 2022 Oct 13;65(19):13413-13435.
Smiles	O=S(C1=CC=C(N2CC(CN3CCC(NC4=NC=NC5=CC=C(N=C54)OCCN(C)C)CC3)C2)C=C1)(C6CC6)=O
Available
Product Description	Menin-MLL inhibitor-22 (compound C20) is an orally active inhibitor of the interaction between menin and mixed lineage leukemia (MLL) (IC50=7 nM). Menin-MLL inhibitor-22 binds menin protein and inhibits cancer cell growth (MV4 cells, IC50=0.3 μM). Menin is a putative tumor suppressor associated with multiple endocrine neoplasia type 1 (MEN-1 syndrome)[1].
StorageTemperature	-20°C, 3 years (Powder)
Shipping	Blue Ice
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	565.73
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 125 mg/mL (ultrasonic)
Target	Epigenetic Reader Domain
Manufacturers Target	Epigenetic Reader Domain
Manufacturers Pathway	Epigenetics
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 50 mg

available

Request delivery time